Session Details

U060 The Gray Zones in High Risk CSCC

Sun, Mar 21, 8:00 AM - 9:00 AM
1 CME Available Focus Session NEW

DESCRIPTION

High risk cutaneous squamous cell carcinoma often presents challenging management decisions where evidence is limited and consensus is lacking. This session will focus on the “gray zones” of CSCC management through practical, case based discussions addressing topics such as imaging, nodal evaluation, adjuvant radiation, systemic therapy, immunosuppression, and management of medically complex patients. Emphasis will be placed on real world decision making, areas of controversy, and individualized patient care.

LEARNING OBJECTIVES

1.

Navigate the “gray zones” of high risk CSCC by applying practical decision making strategies to complex real world cases.

2.

Identify areas of controversy and uncertainty in CSCC management, including imaging, radiation, nodal evaluation, and systemic therapy.

3.

Integrate patient, tumor, and treatment factors to individualize management of high risk and medically complex CSCC patients.

SCHEDULE

8:00 AM

"Who is really high risk?" Staging, calculators, GEP, and ctDNA

Kathryn Shahwan, MD, FAAD

8:12 AM

Nodal evaluation: imaging, SLNB, or watch?

Sean Christensen, MD, PhD, FAAD

8:24 AM

Radiation Therapy: who benefits?

Nina Ran, MD, MS, FAAD

8:36 AM

Perioperative systemic therapy: neoadjuvant and adjuvant approaches

David R. Carr, MD, MPH, FAAD

8:48 AM

Q&A Period

DIRECTOR

David R. Carr, MD, MPH, FAAD

David R. Carr, MD, MPH, FAAD

The Ohio State University

CO-DIRECTOR

Kathryn Shahwan, MD, FAAD

Kathryn Shahwan, MD, FAAD

SPEAKERS

Sean Christensen, MD, PhD, FAAD

Sean Christensen, MD, PhD, FAAD

Yale University School of Medicine

Nina Ran, MD, MS, FAAD

Nina Ran, MD, MS, FAAD

DISCLOSURES

David R. Carr, MD, MPH, FAAD

Regeneron – Investigator(No Compensation Received); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);

Sean Christensen, MD, PhD, FAAD

inhibitor therapeutics – Advisory Board(Fees); Natera – Advisory Board(Honoraria); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);

Nina Ran, MD, MS, FAAD

Chronicle Medical Software – Consultant (1099 relationship)(Fees);

Kathryn Shahwan, MD, FAAD

Highlight Therapeutics – Advisory Board(Honoraria); Sun Pharmaceutical – Advisory Board(Honoraria);